Tamás Resál

11PUBLICATIONS
47CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersMedical infection agents (incl. prions)Major global burdens of disease
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Oct 29, 2024
Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real-Life Retrospective Multicentre Cohort Study.

Péter Bacsur, Daniel Shaham, Zuzana Serclova

|Oct 28, 2024
Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases.

Péter Bacsur, Tamás Resál, Patrícia Sarlós

|Oct 08, 2024
Comparison of risk of malignancy and predictive value of diagnostic categories defined by Papanicolaou Society of Cytopathology system and WHO reporting system for pancreaticobiliary cytopathology in solid pancreatic lesions.

Béla Vasas, Anna Fábián, Zsófia Bősze

|Mar 25, 2024
Accuracy of the Pancolonic Modified Mayo Score in predicting the long-term outcomes of ulcerative colitis: a promising scoring system.

Péter Bacsur, Panu Wetwittayakhlang, Tamás Resál

|Dec 11, 2023
Burnout among European IBD specialists: a survey supported by ECCO.

Anett Dávid, Márta Volosin, Klaudia Farkas

|Sep 26, 2023
Plasminogen Activator Inhibitor 1 Is a Novel Faecal Biomarker for Monitoring Disease Activity and Therapeutic Response in Inflammatory Bowel Diseases.

Boldizsár Jójárt, Tamás Resál, Diána Kata

Pageof 2

Frequent Collaborators

7 joint publications

Tamás Molnár

7 joint publications

Péter Bacsur

5 joint publications

Anna Fábián

5 joint publications

Renáta Bor